Clinical Trials - December 2, 2021
Second dose group fully recruited in Spago Nanomedical study
Spago Nanomedical has annouced that all patients have been recruited in the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix (SND132D). New interim results are expected to be reported in early 2022. SPAGOPIX-01 A total of 6 patients with confirmed breast cancer have been included […]
Intellectual Property - December 8, 2020
Spago Nanomedical receives extended patent protection in Europe
Spago Nanomedical has received notice from the European Patent Office (EPO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. The granted patent will extend protection of SpagoPix in Europe until at least 2038. The second largest market for MRI contrast agents The granted patent, […]
Pharma Business - August 25, 2020
Spago Nanomedical appoints candidate drug in the Tumorad project
The company has decided to formally appoint candidate drug and prepare the preclinical safety program with Tumorad required in preparation for clinical trials. Spago Nanomedical has demonstrated, with statistical significance, that Tumorad reduces tumor growth and extends survival in a mice model for breast cancer. Based on this result and previously communicated progress in the […]
Intellectual Property - April 24, 2020
Spago Nanomedical’s Tumorad patent approved in Japan
Spago Nanomedical has received notice of allowance for the company’s patent application including Tumorad product protection in Japan. ”The patent covers the nanomaterial that is central for the Tumorad-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial […]
Clinical Trials - April 20, 2020
Spago Nanomedical has paused patient recruitment to clinical trial
Spago Nanomedical has momentarily halted its clinical study SPAGOPIX-01 at Uppsala University Hospital due to the COVID-19 pandemic. Uppsala University Hospital has issued internal recommendations for clinical studies as a consequence of the COVID-19 outbreak. Within different departments reprioritizing of resources is made due to this which means that SPAGOPIX-01 momentarily is paused. Through its […]
Clinical Trials - March 24, 2020
New data from Spago Nanomedical
Data from the first dose group in the SpagoPix phase I trial show that SN132D is well tolerated, and provide valuable information for optimization of MRI in the next step. Now that the study continues into the next dose level the company intend to up the pace in patient recruitment by engaging an additional study […]
